News
Regulatory affairsRegulatory Round-up - January 2026
R&D project spotlight: Leveraging advanced analytics for detailed process characterisation in iPSC natural killer cell therapy generationNew data shows continued growth in advanced therapy clinical trials in the UK for 2025, with the number of early-stage trials remaining highRegulatory Round-up - December 2025Minaris and Cell and Gene Therapy Catapult announce collaboration to advance delivery methods for cell and gene therapiesR&D project spotlight: Towards continuous manufacturing for high-dose, cost-efficient rAAV therapiesCGT Catapult leads industry consortium developing universal test to increase the safety and efficiency of stem cell therapiesCGT Catapult to take part in consortium aiming to improve the sustainability of CAR-T manufacturingRegulatory Round-up - November 2025CGT Catapult annual review highlights the role of advanced therapies in supporting Government ambitions for public health and economic growthRegulatory Round-up - October 2025CGT Catapult awarded two Princess Royal Training Awards for its skills and training programmesNew evaluation model finds widespread adoption of cell and gene therapies may unlock billions for the UK economy